Safety of growth hormone replacement therapy in adults

Expert Opinion on Drug Safety

Volumn 3, Issue 4, 2004, Pages 305-316

  Gibney, James ^a   Johannsson, Gudmundur ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adults; Diabetes mellitus; Growth hormone (GH); Insulin like growth factor 1 (IGF 1); Neoplasia; Vascular disease

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOHYDRATE; GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT DISEASE; ARTHRALGIA; BIOSYNTHESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARBOHYDRATE METABOLISM; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHILDHOOD DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HODGKIN DISEASE; HOMEOSTASIS; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; LIPOLYSIS; MITOGENICITY; MORBIDITY; MORTALITY; PERIPHERAL EDEMA; PROVOCATION TEST; REVIEW; SHORT STATURE; TREATMENT INDICATION;

ADULT; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 3543099135     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.4.305     Document Type: Review

References (99)

1. NABARRO JD: Acromegaly. Clin. Endocrinol. (Oxf.) (1987) 26:481-512.
2. ORME SM, MCNALLY RJ, CARTWRIGHT RA, BELCHETZ PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J. Clin. Endocrinol. Metab. (1998) 83:2730-2734.
3. SWEARINGEN B, BARKER FG II, KATZNELSON L et al.: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. (1998) 83:3419-3426.
4. TAKALA J, RUOKONEN E, WEBSTER NR et al.: Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. (1999) 341:785-792.
5. SWERDLOW AJ, HIGGINS CD, ADLARD P, PREECE MA: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet (2002) 360:273-277.
6. CUTFIELD WS, WILTON P, BENNMARKER H et al.: Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet (2000) 355:610-613.
7. MA J, POLLAK MN, GIOVANNUCCI E et al.: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF-)-I and IGF-binding protein-3. J. Natl. Cancer Inst. (1999) 91:620-625.
8. SHANEYFELT T, HUSEIN R, BUBLEY G, MANTZOROS CS: Hormonal predictors of prostate cancer: a meta-analysis. J. Clin. Oncol. (2000) 18:847-853.
9. CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279:563-566.
10. BENGTSSON BÅ, ABS R, BENNMARKER H et al.: The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J. Clin. Endocrinol. Metab. (1999) 84:3929-3935.
11. NO AUTHORS LISTED: Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J. Clin. Endocrinol. Metab. (1998) 83:379-381.
12. HILDING A, HALL K, WIVALL-HELLERYD IL, SAAF M, MELIN AL, THOREN M: Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J. Clin. Endocrinol. Metab. (1999) 84:2013-2019.
13. ROTH J, GLICK SM, YALOW RS, BERSON SA: Hypoglycemia: a potent stimulus to secretion of growth hormone. Science (1963) 140:987-988.
14. SHALET SM, TOOGOOD A, RAHIM A, BRENNAN BMD: The diagnosis of growth hormone deficiency in children and adults. Endocr. Rev. (1998) 19:203-223.
15. HARTMAN ML, CROWE BJ, BILLER BM, HO KK, CLEMMONS DR, CHIPMAN JJ: Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J. Clin. Endocrinol. Metab. (2002) 87:477-485.
16. CARROLL PV, CHRIST ER, BENGTSSON BA et al.: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. (1998) 83:382-395.
17. DE BOER H, BLOK GJ, VAN DER VEEN EA: Clinical aspects of growth hormone deficiency in adults. Endocr. Rev. (1995) 16:63-86.
18. JOHANNSSON G, GRIMBY G, STIBRANT SUNNERHAGEN K, BENGTSSON BÅ: Two years of growth hormone (GH) treatment increases isometric and isokinetic muscle strength in GH-deficient adults. J. Clin. Endocrinol. Metab. (1997) 82:2877-2884.
19. JOHANNSSON G, ROSÉN T, BOSAEUS I, SJÖSTRÖM L, BENGTSSON BÅ: Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. (1996) 81:2865-2873.
20. TER MAATEN JC, DE BOER H, KAMP O, STUURMAN L, VAN DER VEEN EA: Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J. Clin. Endocrinol. Metab. (1999) 84:2373-2380.
21. GIBNEY J, WALLACE JD, SPINKS T et al.: The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. (1999) 84:2596-2602.
22. CHRISOULIDOU A, BESHYAH SA, RUTHERFORD O et al.: Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. (2000) 85:3762-3769.
23. GOTHERSTROM G, SVENSSON J, KORANYI J et al.: A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J. Clin. Endocrinol. Metab. (2001) 86:4657-4665.
24. SVENSSON J, FOWELIN J, LANDIN K, BENGTSSON BÅ, JOHANSSON JO: Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J. Clin. Endocrinol. Metab. (2002) 87:2121-2127.
25. HARTMAN ML, FARIA AC, VANCE ML, JOHNSON ML, THORNER MO, VELDHUIS JD: Temporal structure of in vivo growth hormone secretory events in humans. Am. J. Physiol (1991) 260:E101-E110.
26. HOLMES SJ, SHALET SM: Which adults develop side-effects of growth hormone replacement? Clin. Endocrinol. (1995) 43:143-149.
27. ATTANASIO AF, LAMBERTS SW, MATRANGA AM et al.: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J. Clin. Endocrinol. Metab. (1997) 82:82-88.
28. JOHANNSSON G, ROSEN T, LINDSTEDT G, BOSAEUS I, BENGTSSON BA: Effect of 2 years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol. Metab. (1996) 3:281-286.
29. IRANMANESH A, LIZARRALDE G, VELDHUIS JD: Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol Metab. (1991) 73:1081-1088.
30. BURMAN P, JOHANSSON AG, SIEGBAHN A, VESSBY B, KARLSSON FA: Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J. Clin. Endocrinol Metab. (1997) 82:550-555.
31. JOHANNSSON G, BJARNASON R, BRAMNERT M et al: The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH binding protein, body mass index, age and gender. J. Clin. Endocrinol. Metab. (1996) 81:1575-1581.
32. DE BOER H, BLOK GJ, POPP-SNIJDERS C, STUURMAN L, BAXTER RC, VAN DER VEEN E: Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J. Clin. Endocrinol. Metab. (1996) 81:1371-1377.
33. JOHANNSSON G, ROSÉN T, BENGTSSON BÅ: Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin. Endocrinol. (Oxf.) (1997) 47:571-581.
34. DRAKE WM, COYTE D, CAMACHO-HÜBNER C et al.: Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. (1998) 83:3913-3919.
35. ABS R, BENGTSSON BÅ, HERNBERG-STAHL E et al.: GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin. Endocrinol. (Oxf.) (1999) 50:703-713.
36. MOLLER N, SCHMITZ O, JOORGENSEN JO et al.: Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. (1992) 74:1012-1019.
37. SÖNKSEN PH, GREENWOOD FC, ELLIS JP, LOWY C, RUTHERFORD A, NABARRO JD: Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J. Clin. Endocrinol. Metab. (1967) 27:1418-1430.
38. BESHYAH SA, HENDERSON A, NITHTHYANATHAN R, SHARP P, RICHMOND W, JOHNSTON DG: Metabolic abnormalities in growth hormone deficient adults: II. Carbohydrate tolerance and lipid metabolism. Endocrinol. Metab. (1994) 1:173-180.
39. HEW FL, KOSCHMANN M, CHRISTOPHER M et al.: Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J. Clin. Endocrinol. Metab. (1996) 81:555-564.
40. JOHANSSON JO, FOWELIN J, LANDIN K, LAGER I, BENGTSSON BA: Growth hormone-deficient adults are insulin-resistant. Metabolism (1995) 44:1126-1129.
41. FOWELIN J, ATTVALL S, LAGER I, BENGTSSON BA: Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism (1993) 42:1443-1447.
42. O'NEAL DN, KALFAS A, DUNNING PL et al.: The effects of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J. Clin. Endocrinol. Metab. (1994) 79:975-983.
43. AL-SHOUMER KA, GRAY R, ANYAOKU V et al.: Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin. Endocrinol. (Oxf.) (1998) 48:795-802.
44. BULOW B, ERFURTH EM: A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-1 without significant deterioration in glucose tolerance. Clin. Endocrinol. (Oxf.) (1999) 50:45-55.
45. HWU CM, KWOK CF, LAI TY et al.: Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J. Clin. Endocrinol. Metab. (1997) 82:3285-3292.
46. JØRGENSEN JO, VAHL N, NYHOLM B et al.: Substrate metabolism and insulin sensitivity following long-term growth hormone (GH) replacement therapy in GH-deficient adults. Endocrinol. Metab. (1996) 3:281-286.
47. WEAVER JU, MONSON JP, NOONAN K et al.: The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk facts in hypopituitary adults. J. Clin. Endocrinol. Metab. (1995) 80:153-159.
48. ROSENFALCK AM, MAGHSOUDI S, FISKER S et al.: The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J. Clin. Endocrinol. Metab. (2000) 85:4173-4181.
49. CHRISTOPHER M, HEW FL, OAKLEY M, RANTZAU C, ALFORD F: Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J. Clin. Endocrinol. Metab. (1998) 83:1668-1681.
50. CUNEO RC, SALOMON F, WILES CM, HESP R, SONKSEN PH: Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J. Appl. Physiol. (1991) 70:695-700.
51. NASS R, HUBER RM, KLAUSS V, MULLER OA, SCHOPOHL J, STRASBURGER CJ: Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J. Clin. Endocrinol. Metab. (1995) 80:552-557.
52. WOODHOUSE LJ, ASA SL, THOMAS SG, EZZAT S: Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J. Clin. Endocrinol. Metab. (1999) 84:4570-4577.
53. SACCA L, CITTADINI A, FAZIO S: Growth hormone and the heart. Endocr. Rev. (1994) 15:555-573.
54. CHRIST ER, CUMMINGS MH, WESTWOOD NB et al.: The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. (1997) 82:2985-2990.
55. BOGER RH, SKAMIRA C, BODE-BOGER SM, BRABANT G, VON ZUR MUHLEN A, FROLICH JC: Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J. Clin. Invest. (1996) 98:2706-2713.
56. JOHANNSSON G, SVERRISDOTTIR YB, ELLEGARD L, LUNDBERG PA, HERLITZ H: GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J. Clin. Endocrinol. Metab. (2002) 87:1743-1749.
57. CHRIST ER, CHOWIENCZYK PJ, SONKSEN PH, RUSSEL-JONES DL: Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity. Clin. Endocrinol. (Oxf.) (1999) 51:21-25.
58. EVANS LM, DAVIES JS, ANDERSON RA et al.: The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur. J. Endocrinol. (2000) 142:254-262.
59. PFEIFER M, VERHOVEC R, ZIZEK B, PREZELJ J, POREDOS P, CLAYTON RN: Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. (1999) 84:453-457.
60. BULOW B, HAGMAR L, MIKOCZY Z, NORDSTROM CH, ERFURTH EM: Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. (1997) 46:75-81.
61. NILSSON B, GUSTAVSSON-KADAKA E, BENGTSSON BA, JONSSON B: Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J. Clin. Endocrinol. Metab. (2000) 85:1420-1425.
62. ROSEN T, BENGTSSON BA: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet (1990) 336(8710):285-288.
63. BATES AS, BULLIVANT B, SHEPPARD MC, STEWART PM: Life expectancy following surgery for pituitary tumours. Clin. Endocrinol. (Oxf.) (1999) 50:315-319.
64. BATES AS, VAN HOFF W, JONES PW, CLAYTON RN: The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. (1996) 81:1169-1172.
65. TOMLINSON JW, HOLDEN N, HILLS RK et al.: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet (2001) 357:425-431.
66. BÜLOW B, HAGMAR L, ESKILSSON J, ERFURTH EM: Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. (2000) 85:574-584.
67. ROSENGREN A, WILHELMSEN L, ERIKSSON E, RISBERG B, WEDEL H: Lipoprotein(a) and coronary heart disease. A prospective case-control study in a general population sample of middle aged men. Br. Med. J. (1990) 301:1248-1251.
68. SANDHOLZER C, SAHA N, KARK JD et al.: Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. (1992) 11-1214-1226.
69. OLIVECRONA H, ERICSSON S, BERGLUND L, ANGELIN B: Increased concentrations of serum lipoprotein(a) in response to growth hormone treatment. Br. Med. J. (1993) 306:1726-1727.
70. EDÉN S, WIKLUND O, OSCARSSON J, ROSÉN T, BENGTSSON BÅ: Growth hormone treatment of growth homone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler. Thromb. Vasc. Biol. (1993) 13:296-301.
71. RUSSELL-JONES DL, WATTS GF, WEISSBERGER A et al.: The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin. Endocrinol. (Oxf.) (1994) 41:345-350.
72. JOHANNSSON G, OSCARSSON J, ROSÉN T et al.: Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults: influence of gender and apo (a) and apoE phenotypes. Arterioscler. Thromb. Vasc. Biol. (1995) 15:2142-2150.
73. GARRY P, COLLINS P, DEVLIN JG: An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur. J. Endocrinol. (1996) 134:61-66.
74. O'HALLORAN DJ, WIERINGA G, TSATSOULIS A, SHALET SM: Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in adults with isolated GH deficiency. Clin. Endocrinol. (Oxf.). In Press.
75. NOLTE W, RÄDISCH C, ARMSTRONG VW, HÜFNER M, VON ZUR MÜHLEN A. The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and placebo-controlled trial. Eur. J. Endocrinol. (1997) 137:459-466.
76. WEBSTER JM, STEWART M, AL-MASKARI M et al.: The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults. Atherosclerosis (1997) 133:115-121.
77. VAHL N, JØRGENSEN JO, HANSEN TB et al.: The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. Int. J. Obes. Relat. Metab. Disord. (1998) 22:529-536.
78. LEESE GP, WALLYMAHMED M, WIERINGA G, VANHEYNINGEN C, MACFARLANE IA: Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. Eur. J. Endocrinol. (1999) 140:174-179.
79. PFEIFER M, VERHOVEC M, ZIZEK B, PREZELJ J, POREDOS P, CLAYTON RN: Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. (1999) 84:453-457.
80. LEVINE GN, KEANEY JF, VITA JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. (1995) 332:512-521.
81. BOSTOM AG, CUPPLES LA, JENNER JL et al.: Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J. Am. Med. Assoc. (1996) 276:544-548.
82. JOHANSSON JO, LANDIN K, TENGBORN L, ROSÉN T, BENGTSSON BÅ: High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. Vasc. Biol. (1994) 14:434-437.
83. JOHANSSON JO, LANDIN K, JOHANNSSON G, TENGBORN L, BENGTSSON BÅ: Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb. Haemost. (1996) 76:422-428.
84. CHRIST ER, CUMMINGS MH, LUMB PJ, CROOK MA, SONKSEN PH, RUSSELL-JONES DL: Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. Clin. Endocrinol. (Oxf.) (1999) 51:173-179.
85. SESMILO G, BILLER BM, LLEVADOT J et al.: Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. (2000) 133:111-122.
86. SESMILO G, BILLER BM, LLEVADOT J et al.: Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. J. Clin. Endocrinol. Metab. (2001) 86:1518-1524.
87. BESSON A, SALEMI S, GALLATI S et al.: Reduced longevity in untreated patients with isolated growth hormone deficiency. J. Clin. Endocrinol. Metab. (2003) 88:3664-3667.
88. BRADA M, RAJAN B, TRAISH D et al.: The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin. Endocrinol. (Oxf.) (1993) 38:571-578.
89. TURNER HE, STRATTON IM, BYRNE JV, ADAMS CB, WASS JA: Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clin. Endocrinol (Oxf.) (1999) 51:281-284.
90. ATTANASIO AF, LAMBERTS SW, MATRANGA AM et al.: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J. Clin. Endocrinol. Metab. (1997) 82:82-88.
91. MÅRD G, LUNDIN K, BORG G, JONSSON B, LINDBERG A: Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol. Metab. (1994) 1(Suppl. A): 43-49.
92. CUNEO RC, JUDD S, WALLACE JD et al.: The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J. Clin. Endocrinol Metab. (1998) 83:107-116.
93. BENGTSSON BA, EDEN S, ERNEST I, ODEN A, SJOGREN B: Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scand. (1988) 223:327-335.
94. DELHOUGNE B, DENEUX C, ABS R et al.: The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J. Clin. Endocrinol. Metab. (1995) 80:3223-3226.
95. JENKINS PJ, FAIRCLOUGH PD, RICHARDS T et al.: Acromegaly, colonic polyps and carcinoma. Clin. Endocrinol (Oxf.) (1997) 47:17-22.
96. RENEHAN AG, O'DWYER ST, SHALET SM: Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. Gut (2000) 46:440-441.
97. HANKINSON SE, WILLETT WC, COLDITZ GA et al.: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 351:1393-1396.
98. BENGTSSON BÅ, KOPPESCHAAR HP, ABS R et al.: Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. J. Clin. Endocrinol. Metab. (1999) 84:4291-4292.
99. SVENSSON J, BENGTSSON BÅ, ODEN A, ROSÉN T, JOHANNSSON G: The incidence of malignant disease and cardiovascular morbidity in hypopituitary patients with or without growth hormone replacement therapy. The Endocrine Society Annual Meeting, Philadelphia, USA (2003):344.